Inhibikase Therapeutics(IKT) Stock Price Today

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

H.C. Wainwright Maintains Inhibikase Therapeutics(IKT.US) With Hold Rating
Moomoo News13:32 ET · Ratings
Express News | HC Wainwright & Co. Reiterates Neutral on Inhibikase Therapeuticsto Neutral
Benzinga13:26 ET
Inhibikase Therapeutics (IKT) Receives a Hold From H.C. Wainwright
TipRanksMar 28 09:15 ET
Inhibikase Therapeutics | 10-K: Annual report
SECMar 27 16:20 ET · Announcements
Inhibikase Therapeutics 2024 Loss/Shr $1.16 >IKT
Dow JonesMar 27 16:02 ET
Press Release: Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
Dow JonesMar 27 16:01 ET

Comments

Teddy123

Yesterday 13:10

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

$Inhibikase Therapeutics (IKT.US)$
Inhibikase Secures Future: $110M Funding, FDA Green Light, and New Leadership Fuel Growth

Trytosaveabit

Jan 30 06:08

update

$Inhibikase Therapeutics (IKT.US)$ Reuters
4 mins ago
Inhibikase Therapeutics Inc - 201 Trial Met Primary Endpoint of Safety and Tolerability!
Inhibikase Therapeutics Inc - Risvodetinib Treatment Did Not Show Improvement in Top Hierarchical Efficacy Measure

2

Jaguar8

Dec 16, 2024 10:58

🔶December 2024 Upcoming Catalysts. Save it. In alphabetical order

$ABVC BioPharma (ABVC.US)$ - Progress continues in our ADHD program with Phase IIb trials at multiple prominent sites. We aim to have an interim report by Q4 2024. ABV-1601 for MDD in cancer patients has completed Phase I study preparation, including the Site Initiation Visit (SIV). The study is set to initiate by the end of 2024.
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...

28

9

7

Jaguar8

Nov 14, 2024 21:38

NEWS ER

$Inhibikase Therapeutics (IKT.US)$
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
Positive
Secured significant financing of up to $275 million, including $110 million immediate private placement
Received FDA Study May Proceed letter for IkT-001Pro PAH trial
High trial completion rate with 120 of 126 patients completing the Phase 2 201 Trial
Negative
Increased net loss to $5.8 million in Q3 2024 from $4.6 million in Q3 2023
R&D expenses incr...

Jaguar8

Oct 29, 2024 09:18

Put on list Multiple 13Gs since last week till today. Likely a good PR coming up. Low float

$Inhibikase Therapeutics (IKT.US)$

2

IKT Inhibikase Therapeutics

Trade Overview

Capital Trend

News

Comments

Market Insights